Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Convertible Debt (2021 - 2024)

Historic Convertible Debt for Trinity Biotech (TRIB) over the last 4 years, with Q4 2024 value amounting to $15.4 million.

  • Trinity Biotech's Convertible Debt rose 590.7% to $15.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $15.4 million, marking a year-over-year increase of 590.7%. This contributed to the annual value of $15.4 million for FY2024, which is 590.7% up from last year.
  • Latest data reveals that Trinity Biotech reported Convertible Debt of $15.4 million as of Q4 2024, which was up 590.7% from $15.2 million recorded in Q3 2024.
  • Trinity Biotech's Convertible Debt's 5-year high stood at $83.3 million during Q4 2021, with a 5-year trough of $13.4 million in Q2 2022.
  • Its 4-year average for Convertible Debt is $20.1 million, with a median of $14.4 million in 2023.
  • As far as peak fluctuations go, Trinity Biotech's Convertible Debt crashed by 8350.06% in 2022, and later surged by 590.7% in 2024.
  • Trinity Biotech's Convertible Debt (Quarter) stood at $83.3 million in 2021, then plummeted by 83.5% to $13.7 million in 2022, then rose by 5.79% to $14.5 million in 2023, then rose by 5.91% to $15.4 million in 2024.
  • Its last three reported values are $15.4 million in Q4 2024, $15.2 million for Q3 2024, and $15.0 million during Q2 2024.